VIVIMEDLAB2024-01-012024-03-31 VIVIMEDLAB2024-01-012024-03-31 VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member VIVIMEDLAB2024-03-31 VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member VIVIMEDLAB2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member VIVIMEDLAB2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member VIVIMEDLAB2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532660 VIVIMEDLAB na Vivimed Labs Limited Equity 2023-04-01 2024-03-31 2024-11-14 2024-11-07 INR Millions Yearly 16:00:00 22:20:00 2024-11-14 2024-11-14 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2024-01-01 2024-03-31 Unaudited Consolidated 386157000.00 76247000.00 462404000.00 338863000.00 -14052000.00 -185970000.00 69905000.00 -333338000.00 58342000.00 462123000.00 395873000.00 66531000.00 0.00 66531000.00 180000.00 13730000.00 13910000.00 0.00 52621000.00 0.00 0.00 0.00 0.00 52621000.00 5630000.00 58251000.00 0.00 0.00 0.00 0.00 165828000.00 2 0.64 0.62 0.00 0.00 0.64 0.62 0.00 0.00 0.00 1. The above unaudited consolidated financial results of Vivimed Labs Limited ( the Company ) as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 14, 2024. The statutory auditors of the Company have carried out a audit on consolidated financial results and expressed a modified conclusion thereon. 2. These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ( SEBI ). 3. The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs.3,751.06 million as on 31.03.2024 as per books of Account. All the loan accounts outstanding as on 31.03.2024 are classified as NPA by the banks. An amount of Rs.453.34 million pertaining to Interest for the twelve months period ended on 31st March 2024 has been reversed as the company is negotiating with Lenders for One Time Settlement. 4. The proposed sale of part of the speciality Chemical Business of the company couldnot be completed due to nonpayment of the balance consideration. However, in view of the proposed sale, the Operations of Speciality Chemicals at Bidar Plant were on Negligible. As such, leftover inventory of Rs.269.18 Mn at Bidar Plant became obsolescence / expired and disposed off . 5. The Company has carried out the reconciliation of pending security deposits as per accounts and based on the reconciliation, it is identified that certain deposits have been recovered. Some of the security deposits have been forfeited by the respective parties. Accordingly, the required entry has been passed in books of accounts during the year. 6. In line with provisions of Ind AS 108 Operating segments, during the year, the Company has primarily two segments speciality chemicals and Pharma and accordingly considered under reportable segments by the Company 7.Corresponding numbers of previous period / year have been regrouped, wherever necessary. Multi segment 2023-04-01 2024-03-31 Unaudited Consolidated 1490710000.00 99760000.00 1590470000.00 895450000.00 0.00 -180710000.00 341550000.00 24320000.00 199406000.00 768680000.00 2048696000.00 -458226000.00 0.00 -458226000.00 180000.00 -3950000.00 -3770000.00 0.00 -454456000.00 0.00 0.00 0.00 0.00 -454456000.00 5630000.00 -448826000.00 0.00 0.00 0.00 0.00 165828000.00 2 0.00 -5.48 -5.32 0.00 0.00 -5.48 -5.32 0.00 0.00 0.00 Other Expenses 403833000.00 Prior Period Expenses 58290000.00 Other Expenses 710390000.00 Prior Period Expenses 58290000.00 0.00 2628600000.00 206510000.00 0.00 0.00 1550650000.00 1684950000.00 0.00 0.00 12557000.00 12557000.00 6083267000.00 640620000.00 0.00 828197000.00 20260000.00 0.00 414210000.00 701530000.00 1964197000.00 100130000.00 720890000.00 3425837000.00 0.00 0.00 9509104000.00 165828000.00 -220440000.00 -54612000.00 -54612000.00 635650000.00 4679180000.00 5314830000.00 49000000.00 90330000.00 0.00 6300000.00 5460460000.00 3133640000.00 440686000.00 173920000.00 3748246000.00 160540000.00 13890000.00 180580000.00 0.00 4103256000.00 0.00 0.00 9563716000.00 9509104000.00 Pharma Business 353846000.00 Speciality Chemicals Business 32308000.00 Pharma Business 1431730000.00 Speciality Chemicals Business 58980000.00 386154000.00 1490710000.00 386154000.00 1490710000.00 Pharma Business -93638000.00 Speciality Chemicals Business -249422000.00 Pharma Business -273340000.00 Speciality Chemicals Business -260330000.00 -343060000.00 -533670000.00 -333338000.00 24320000.00 -76250000.00 Segmental capital employed As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangebility across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table. -99760000.00 66528000.00 -458230000.00 Pharma Business 0.00 Speciality Chemicals Business 0.00 0.00 Pharma Business 0.00 Speciality Chemicals Business 0.00 0.00 24320000.00 156980000.00 -86640000.00 0.00 -122680000.00 0.00 0.00 0.00 0.00 -111620000.00 0.00 150990000.00 0.00 199410000.00 0.00 6610000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 217370000.00 -240856000.00 0.00 0.00 0.00 -940000.00 0.00 -239916000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -20390000.00 0.00 303260000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 282870000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -36000000.00 0.00 0.00 0.00 0.00 24320000.00 0.00 0.00 -60320000.00 -17366000.00 0.00 -17366000.00 37620000.00 20254000.00 -5630000.00 -5630000.00 0.00 0.00